Table 1 Characteristics and therapy of patients with EGPA ( n = 19)
Age at the time of the study (years) | 58.9 ± 16.9* |
Male/Female | 7/12 |
Atopic/nonatopic | 6/13 |
Age at onset of EGPA (years) | 52.6 ± 18.4 |
Duration of EGPA (years) | 6.8 ± 3.6 |
At onset of EGPA | Â |
WBCs (/μL) | 15561 ± 6238 |
Eosinophils (/μL) | 8344 ± 5887 |
MPO-ANCA positive/negative | 6/13 |
Clinical manifestations of EGPA | Â |
Number of organs involved | 5.4 ± 1.9 |
Five-Factor Score 1996 | 1.1 ± 0.8 |
Five-Factor Score 2009 | 1.4 ± 0.9 |
Additional organ involvement | Â |
Asthma (yes/no) | 19/0 |
Sinusitis (yes/no) | 18/1 |
Lung (yes/no) | 11/6 |
Multiple mononeuritis (yes/no) | 19/0 |
Lowest MMT score | 3.2 ± 1.1 |
Heart (yes/no) | 14/5 |
Gastrointestinal (yes/no) | 16/3 |
Renal (yes/no) | 7/10 |
Skin (yes/no) | 12/5 |
Central nervous system (yes/no) | 4/15 |
Arthralgia (yes/no) | 9/10 |
Myalgia (yes/no) | 7/10 |
BVAS at onset | 35.1 ± 10.1 |
Initial treatment | Â |
Initial dose of PSL (mg) | 44.2 ± 10.7 |
Immunosuppressant at initial treatment (yes/no) | 12/7 |
CYC/AZA/CSA/MTX/RTX | 10/1/1/0/0 |